- Home
- CABR vs TXMD Comparison
CABR vs TXMD Comparison
Compare CABR & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABR
- TXMD
- Stock Information
- Founded
- CABR 2020
- TXMD 2008
- Country
- CABR United States
- TXMD United States
- Employees
- CABR N/A
- TXMD N/A
- Industry
- CABR Package Goods/Cosmetics
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- CABR Consumer Discretionary
- TXMD Health Care
- Exchange
- CABR Nasdaq
- TXMD Nasdaq
- Market Cap
- CABR 14.1M
- TXMD 12.3M
- IPO Year
- CABR 2025
- TXMD N/A
- Fundamental
- Price
- CABR $0.84
- TXMD $1.54
- Analyst Decision
- CABR
- TXMD
- Analyst Count
- CABR 0
- TXMD 0
- Target Price
- CABR N/A
- TXMD N/A
- AVG Volume (30 Days)
- CABR 1.1M
- TXMD 123.8K
- Earning Date
- CABR 01-01-0001
- TXMD 11-12-2025
- Dividend Yield
- CABR N/A
- TXMD N/A
- EPS Growth
- CABR N/A
- TXMD N/A
- EPS
- CABR N/A
- TXMD 0.03
- Revenue
- CABR $4,493.00
- TXMD $2,796,000.00
- Revenue This Year
- CABR N/A
- TXMD $427.09
- Revenue Next Year
- CABR N/A
- TXMD N/A
- P/E Ratio
- CABR N/A
- TXMD $75.12
- Revenue Growth
- CABR N/A
- TXMD 75.19
- 52 Week Low
- CABR $0.75
- TXMD $0.70
- 52 Week High
- CABR $3.20
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- CABR N/A
- TXMD 56.44
- Support Level
- CABR N/A
- TXMD $1.11
- Resistance Level
- CABR N/A
- TXMD $1.46
- Average True Range (ATR)
- CABR 0.00
- TXMD 0.19
- MACD
- CABR 0.00
- TXMD 0.05
- Stochastic Oscillator
- CABR 0.00
- TXMD 41.41
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.